S'abonner

EARLY TRYPSINOGEN ACTIVATION IN ACUTE PANCREATITIS - 06/09/11

Doi : 10.1016/S0025-7125(05)70239-X 
Markus M. Lerch, MD a, Fred S. Gorelick, MD b
a Department of Medicine, Westfälische Wilhelms-Universität, Münster, Germany (MML) 
b Department of Medicine and Cell Biology, VA Connecticut Healthcare System, Yale University School of Medicine, West Haven, Connecticut (FSG) 

Résumé

The exocrine pancreas synthesizes and secretes more protein per cell than any other exocrine organ. Much of its protein secretion consists of digestive proenzymes, called zymogens, that require cleavage of an activation peptide by a protease. After entering the small intestine, the pancreatic zymogen trypsinogen is first processed to trypsin by the intestinal protease, enterokinase. Trypsin then proteolytically processes the other pancreatic zymogens to their active forms. Under physiologic conditions, pancreatic proteases remain inactive during their synthesis, intracellular transport, secretion from acinar cells, and transit through the pancreatic duct. They become active only when they reach the lumen of the small intestine. About a century ago, Chiari suggested that the pancreas of patients who had died during episodes of acute necrotizing pancreatitis “had succumbed to its own digestive properties” and postulated that pancreatic autodigestion is the underlying pathophysiologic mechanism of the disease.8 Since then, many attempts have been made to prove or disprove the role of a premature and intracellular zymogen activation as an initial or an initiating event in the course of acute pancreatitis. More recent advances in biochemical and molecular techniques have allowed investigators to address some of these questions conclusively.

Much of the current knowledge regarding the onset of pancreatitis was not gained from studies involving the human pancreas or patients with pancreatitis but from animal or isolated cell models. There are several reasons why these models have been used: (1) The pancreas is a rather inaccessible organ because of its anatomic location in the retroperitoneal space; in contrast to the colon or stomach, biopsy specimens of human pancreas are difficult to obtain for ethical and medical reasons. (2) Patients who are admitted to the hospital with acute pancreatitis have usually passed through the initial stages of the disease in which the triggering early events could have been studied. Particularly the autodigestive process that characterizes this disease has remained a significant impediment for investigations that address initiating pathophysiologic events. The issue of premature protease activation has mostly been studied in animal models of the disease.16, 40, 41 These models can be experimentally controlled, are highly reproducible, and recapitulate many of the cellular events that are associated with clinical disease.

Although this article focuses on zymogen activation within the acinar cell, other mechanisms undoubtedly contribute to pancreatic injury.16 The activation of extracellular proteases, an increased vascular permeability, and endothelial injury are all features of acute pancreatitis and have been shown to contribute to pancreatic edema, decreased pancreatic blood flow, ischemic injury, and disease progression.25, 49 Potentially damaging free radicals are detected within the pancreas soon after the induction of pancreatitis,58 and free radical scavengers have been reported to improve the course of experimental disease models.54 Finally, the release of cytokines by acinar cells and activated inflammatory cells and the expression of adhesion factors promote the harmful inflammatory response that begins within hours after the onset of experimental pancreatitis.59 Although most of these factors contribute to the severity and ultimate clinical outcome of acute pancreatitis, they are probably not involved in the early phase of intracellular zymogen activation and are not discussed further here.

Le texte complet de cet article est disponible en PDF.

Plan


 Address reprint requests to Markus M. Lerch, MD, Department of Medicine B, Westfälische Wilhelms-Universität, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany, e-mail: markus.lerch@uni-muenster.de
Supported by grants from the Deutsche Forschungsgemeinschaft and the Federal Ministry for Education and Research of Germany (MML) and the Veterans Administration and National Institutes of Health (FSG).


© 2000  W. B. Saunders Company. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 3

P. 549-563 - mai 2000 Retour au numéro
Article précédent Article précédent
  • GENETIC PREDISPOSITIONS TO ACUTE AND CHRONIC PANCREATITIS
  • David C. Whitcomb
| Article suivant Article suivant
  • RISK FACTORS FOR CANCER IN HEREDITARY PANCREATITIS
  • Albert B. Lowenfels, Patrick Maisonneuve, David C. Whitcomb

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.